Evolve BioSystems

21 articles with Evolve BioSystems

• Investors Continue to Support Breakthrough Research on Infant Gut Health

  5/25/2021

  Evolve BioSystems, Inc., a privately-held leading microbiome company, announced the second and final close of its Series D round of funding exceeding $65 million, led by investors Cargill and Manna Tree.

• Evolve BioSystems, Inc. Announces the Use of Activated B. infantis EVC001 by International Consortium to Study the Prevention of Type 1 Diabetes in Children

  3/11/2021

  Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children.

• Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant Gut Health

  2/8/2021

  Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health.

• Evolve BioSystems, Inc. announces Dr. Minhthy Nguyen as Senior Vice President of Research & Development, further advancing its position as the leader in infant gut health

  7/28/2020

  Evolve BioSystems announced today that Dr. Minhthy Nguyen , PhD, has joined the company as Senior Vice President, Research & Development. Dr. Nguyen joins the company in anticipation of the pending announcement of positive results from several large clinical studies, positioning the company for a material leap forward in the infan

• Infant Fecal pH Revealed as a Critical Indicator of Infant Gut Health and Resistance against Gut Pathogen Invasion

  4/9/2020

  Updated Infant Fecal pH Range Identifies Deficiency of Beneficial Bacteria in Infant Gut Microbiome

• Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis

  3/26/2020

  Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis.

• RB and Evolve BioSystems Team Up to Advance Infant Gut Health

  12/5/2019

  RB and Evolve BioSystems announce a partnership in the sale of Evivo®, Evolve BioSystems' infant probiotic.

• Evolve BioSystems And The Regents Of The University Of California Jointly File Patent Infringement Complaint Against Abbott Laboratories Regarding Infant Probiotic

  9/30/2019

  Evolve BioSystems and the Regents of the University of California have jointly filed and served a patent infringement complaint against Abbott Laboratories.

• Intestinal Inflammation in Infants Dramatically Reduced with Bifidobacterium infantis

  9/10/2019

  University of California, Davis Study Shows up to 98% Reduction of Intestinal Inflammation Markers Linked to Colic, Eczema, Asthma and Diabetes

• Novel Probiotic Strain Dramatically Reduces Antibiotic Resistance In Infants

  8/14/2019

  Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Global Health Epidemic

• First-Ever Rapid Response Test for Levels of Bifidobacterium in Baby's Gut Microbiome

  9/20/2018

  Evivo Stool Test Prototype Provides Clear Window into Infant Gut Health

• Significant Reduction in Pathogenic Gut Bacteria Lowers Potential for Infection Risk in Infants Fed B. infantis EVC001

  7/18/2018

  Evolve BioSystems Demonstrates 93 Percent Drop in Common Pathogens such as E. coli, C. difficile

• Evolve BioSystems Announces $40 Million Series C Financing to Expand its Flagship Infant Probiotic Product Evivo

  6/13/2018

  Bill & Melinda Gates Foundation, Li Ka Shing Foundation Lead New Funding Round to Expand Groundbreaking Progress in Restoring Infant Gut Microbiome and to Lay a Global Foundation for Long-Term Nutritional and Immune Health

• Evolve BioSystems Partners With King’s College London to Resolve Gut Dysbiosis in C-Section Delivered Infants

  2/1/2018

  The study will investigate the impact of dietary B. infantis EVC001, combined with breastfeeding, in restoring intestinal Bifidobacterium in infants delivered by Caesarean-section, a known cause of infant gut dysbiosis.

• Evolve BioSystems' Activated B. infantis EVC001 Demonstrates Substantial and Persistent Remodeling of the Infant Gut Microbiome

  12/6/2017

  The study showed that providing dietary B. infantis EVC001 resulted in rapid, substantial, and persistent remodeling of the gut microbiome in breastfed infants.

• Evolve BioSystems' Evivo Gains Health Canada Approval, Providing First International Expansion Opportunity

  10/30/2017

  The license, granted by Health Canada, states that Evivo is safe to give once a day to babies under 1 year of age.

• Evolve BioSystems Announces Timothy B. Brown As New CEO, David Kyle Named Executive Chairman And Chief Scientific Officer

  8/1/2017

• Evolve BioSystems Release: Evivo Protects Babies From The Inside Out

  7/12/2017

• Evolve BioSystems Completes $20 Million Series B Financing

  5/31/2017

• Evolve BioSystems Successfully Defends European Patent Opposition By Danone, Maintaining Their Position As Leaders In The Infant Gut Microbiome Space

  12/20/2016